Plain-English translation of NCT06637423 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called that is delivered directly into the bladder to treat bladder cancer that keeps recurring. Researchers want to find out if this medication is safe, how well patients tolerate it, and what dose works best. The goal is to gather enough information to plan larger studies to see how well this treatment actually works against recurring bladder tumors.
Current treatments for recurring bladder cancer don't work well enough for all patients, and some people experience the cancer coming back again and again. This trial is exploring whether delivering this medication directly into the bladder—rather than through the bloodstream—might be more effective and cause fewer side effects.
Over 6 weeks, you would receive the medication instilled directly into your bladder (similar to a catheter procedure). You would likely need to visit the clinic multiple times during this period for the treatments and safety monitoring. After the 6-week treatment period ends, you would continue to be monitored to see how well the treatment worked and to watch for any side effects.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States
Canada